Business Context and Reporting Period
Company: MediciNova, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: MediciNova is a development-stage biopharmaceutical company focused on acquiring and developing novel small molecule therapeutics, primarily through strategic alliances with Japanese pharmaceutical companies. The company has no approved products for commercial sale and has incurred significant net losses since inception.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2007 | Six Months Ended June 30, 2006 |
|---|---|---|
| Revenues | $0 | $258,876 |
| Net Loss | $(35,683,378) | $(15,682,390) |
| Net Loss Per Share (Basic & Diluted) | $(3.08) | $(1.69) |
| Research & Development Expenses | $32,060,611 | $14,260,567 |
| General & Administrative Expenses | $6,059,514 | $4,402,416 |
| Cash and Cash Equivalents (End of Period) | $12,654,344 | $15,075,197 |
| Marketable Securities (Available-for-Sale) | $73,205,968 | $95,716,690 |
| Total Current Assets | $89,764,145 | $110,670,180 |
| Total Current Liabilities | $12,540,355 | $10,568,543 |
| Accumulated Deficit (Inception to Date) | $(191,837,515) | $(156,154,136) |
Liquidity: As of June 30, 2007, the company held approximately $85.9 million in cash, cash equivalents, and marketable securities. Management believes these resources are sufficient to fund operations through June 30, 2008.
Material Changes vs. Prior Period
- Revenue Decline: Revenues dropped to zero for the six months ended June 30, 2007, compared to $258,876 in the prior year period. This is due to the termination of the master services agreement with Argenes, Inc. and the completion of the agreement with Asahi Kasei Pharma Corporation.
- Increased Net Loss: Net loss more than doubled to $35.7 million from $15.7 million year-over-year. This was driven primarily by a $17.8 million increase in R&D expenses.
- R&D Expense Surge: R&D expenses increased significantly due to the advancement of clinical trials for MN-305 (insomnia) and MN-221 (status asthmaticus/preterm labor), and specifically due to $13.6 million in costs related to the advancement and subsequent termination of the Phase III trial for MN-001 (bronchial asthma).
- Capital Raise: The company completed a public offering of 1,000,000 shares of common stock on February 1, 2007, raising approximately $10.6 million in net proceeds.
Guidance, Outlook, and Risks
Management Commentary and Strategy
On June 26, 2007, the company announced a strategic initiative to focus resources on two key assets: MN-221 (status asthmaticus/preterm labor) and MN-166 (multiple sclerosis). Consequently, the company discontinued the clinical development of MN-001 in its immediate-release formulation for bronchial asthma to focus on developing a once-per-day oral dosage form.
Clinical Developments
- MN-166 (Multiple Sclerosis): Announced positive one-year results from a Phase II trial showing a significant increase in the proportion of patients remaining relapse-free and a significant reduction in brain volume loss compared to placebo.
- MN-001 (Interstitial Cystitis): A Phase II/III trial completed in Q1 2007 did not show a statistically significant clinical benefit on the primary endpoint at eight weeks, though a trend was observed at four weeks.
- MN-305 (Insomnia): Initiated a Phase II clinical study for primary insomnia based on positive observations in a Generalized Anxiety Disorder trial.
Risks and Contingencies
- Legal Proceedings: A lawsuit was filed on April 30, 2007, by a participant in a clinical trial alleging permanent injuries to her daughter in utero. The company intends to defend vigorously, and its insurance carrier has assumed the defense. Management does not believe this will have a material adverse effect at this time.
- Liquidity Risk: The company expects to continue incurring significant losses and will require additional financing in the future to fund operations beyond mid-2008. There is no guarantee that capital will be available on acceptable terms.
- Development Risk: As a development-stage company, the company faces significant risks regarding the success of clinical trials, regulatory approvals, and the ability to commercialize products.
Key Facts for Investor Verification
- Cash Runway: Verify if the $85.9 million in liquid assets is sufficient to fund the revised development strategy through June 2008 without further dilution.
- MN-001 Termination Costs: Confirm the final costs associated with terminating the Phase III bronchial asthma trial, currently estimated at $2.7 million for the quarter.
- Legal Exposure: Monitor the status of the clinical trial participant lawsuit and any potential impact on insurance coverage or future trial enrollments.
- Investment Portfolio: Review the composition of the $73.2 million in marketable securities, specifically the exposure to Auction Rate Securities (ARS), which can face liquidity issues if auctions fail.
- Stock-Based Compensation: Note that $2.1 million of the net loss for the six-month period was attributable to non-cash stock-based compensation.